上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
11期
50-53
,共4页
罕用药%Web of Science%文献计量学
罕用藥%Web of Science%文獻計量學
한용약%Web of Science%문헌계량학
orphan drug%Web of Science%bibliometrics
目的：从文献计量学的角度分析20多年来罕用药研究的发展状况。方法：利用Science Citation Index Expanded引文数据库检索1992-2014年间罕用药研究的文献，分别从罕用药研究的国家、机构、作者的发文量、被引频次、期刊分布及研究方向等进行统计分析。结果：1992-2014年间共有罕用药文献2050篇，分布于250种期刊，近10年来文献量逐渐增多，主要研究方向是药理学、生物化学分子生物学、肿瘤学、神经科学神经病学、化学、细胞生物学等。美国、英国、法国、瑞士等国在该领域内影响力大。结论：罕见病日益引起人们的关注，美国、欧盟等发达国家在罕用药研究领域占有绝对优势，中国还处在起步阶段，应进一步提高对此项研究的投入和研究水平。
目的：從文獻計量學的角度分析20多年來罕用藥研究的髮展狀況。方法：利用Science Citation Index Expanded引文數據庫檢索1992-2014年間罕用藥研究的文獻，分彆從罕用藥研究的國傢、機構、作者的髮文量、被引頻次、期刊分佈及研究方嚮等進行統計分析。結果：1992-2014年間共有罕用藥文獻2050篇，分佈于250種期刊，近10年來文獻量逐漸增多，主要研究方嚮是藥理學、生物化學分子生物學、腫瘤學、神經科學神經病學、化學、細胞生物學等。美國、英國、法國、瑞士等國在該領域內影響力大。結論：罕見病日益引起人們的關註，美國、歐盟等髮達國傢在罕用藥研究領域佔有絕對優勢，中國還處在起步階段，應進一步提高對此項研究的投入和研究水平。
목적：종문헌계량학적각도분석20다년래한용약연구적발전상황。방법：이용Science Citation Index Expanded인문수거고검색1992-2014년간한용약연구적문헌，분별종한용약연구적국가、궤구、작자적발문량、피인빈차、기간분포급연구방향등진행통계분석。결과：1992-2014년간공유한용약문헌2050편，분포우250충기간，근10년래문헌량축점증다，주요연구방향시약이학、생물화학분자생물학、종류학、신경과학신경병학、화학、세포생물학등。미국、영국、법국、서사등국재해영역내영향력대。결론：한견병일익인기인문적관주，미국、구맹등발체국가재한용약연구영역점유절대우세，중국환처재기보계단，응진일보제고대차항연구적투입화연구수평。
Objective:To analyze the status of research on orphan drug from 1992 to 2014 using a bibliometric approach.Methods: Literature on orphan drug from the Web of Science’s Science Citation Index Expanded database was searched. The search results were analyzed with regard to the number of articles, frequency of citations by country, institution and author, journal of publication, and ifelds covered by the article.Results: In total 2 050 articles related to orphan drug were published in 250 journals from 1992 to 2014, covering pharmacology, biochemistry, molecular biology, oncology, neuroscience, neurology, chemistry, cell biology, etc. The number of papers has increased apparently over the last 10 years. The United States, Britain, France, Switzerland have played important roles in the orphan drug research in the world.Conclusion: Rare disease has attracted more and more attention. US, EU and other developed countries play a leading role in research on orphan drug. China is still in her infancy, we should improve the level of investment and research on orphan drug.
